Skip to main content

Reflections on NICE’s Uptake of New Methods: Past, Present, and the 2020 Review

A Commentary to this article was published on 24 April 2020

The Original Article was published on 13 January 2020

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Sculpher M, Palmer S. After 20 years of using economic evaluation, should NICE be considered a methods innovator? Pharmacoeconomics. 2020. https://doi.org/10.1007/s40273-019-00882-6.

    Article  PubMed  Google Scholar 

  2. 2.

    National Institute for Health and Care Excellence. Changes we are making to health technology evaluation; 2020. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation. Accessed 17 Jan 2020.

  3. 3.

    National Institute for Health and Care Excellence. The principles that guide the development of NICE guidance and standards. In: National Institute for Health and Care Excellence Public Board Meeting, 20 November 2019. https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Public-board-meetings/agenda-and-papers-nov-19.pdf. Accessed 17 Jan 2020.

  4. 4.

    NHS England. The Accelerated Access Collaborative; 2020. https://www.england.nhs.uk/ourwork/innovation/accel-access/. Accessed 17 Jan 2020.

  5. 5.

    NHS England. The Commercial Framework for Medicines; 2020. https://www.engage.england.nhs.uk/consultation/nhs-commercial-framework-for-medicines/. Accessed 17 Jan 2020.

  6. 6.

    National Institute for Health and Care Excellence. Review of methods for health technology evaluation programmes. In: National Institute for Health and Care Excellence Public Board Meeting, 17 July 2019. https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Public-board-meetings/agenda-and-papers-july-19.pdf. Accessed 17 Jan 2020.

Download references

Acknowledgements

The authors are grateful for the comments and suggestions made by Mirella Marlow, Rebecca Smith and Helen Knight at NICE.

Author information

Affiliations

Authors

Contributions

Both authors contributed to the writing of the manuscript and signed off the final version.

Corresponding author

Correspondence to Meindert Boysen.

Ethics declarations

Conflict of interest

The authors are employed by the National Institute for Health and Care Excellence; MB is a member of the NICE methods review steering group, and IW is a member of the NICE methods review steering and working groups. MB is on the Board of Directors for the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). No specific funding was used for work detailed in this paper.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Boysen, M., Watson, I. Reflections on NICE’s Uptake of New Methods: Past, Present, and the 2020 Review. PharmacoEconomics 38, 243–245 (2020). https://doi.org/10.1007/s40273-020-00888-5

Download citation